Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy
1
Control of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, 08036, Barcelona, Spain
2
Faculty of Medicine, University of Sydney Medical School, Division of Pediatrics and Child Health, Westmead Children's Hospital, Locked Bag 4001, Westmead NSW 2145, Sydney, Australia
3
School of Anatomy Physiology & Human Biology and The Harry Perkins Institute for Medical Research (CCTRM), the University of Western Australia, 6 Verdun St, Nedlands WA 6009, Perth, Australia
*
Author to whom correspondence should be addressed.
Academic Editor: David T. Harris
J. Clin. Med. 2015, 4(2), 243-259; https://doi.org/10.3390/jcm4020243
Received: 1 October 2014
/
Accepted: 3 December 2014
/
Published: 29 January 2015
(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)
The use of adult myogenic stem cells as a cell therapy for skeletal muscle regeneration has been attempted for decades, with only moderate success. Myogenic progenitors (MP) made from induced pluripotent stem cells (iPSCs) are promising candidates for stem cell therapy to regenerate skeletal muscle since they allow allogenic transplantation, can be produced in large quantities, and, as compared to adult myoblasts, present more embryonic-like features and more proliferative capacity in vitro, which indicates a potential for more self-renewal and regenerative capacity in vivo. Different approaches have been described to make myogenic progenitors either by gene overexpression or by directed differentiation through culture conditions, and several myopathies have already been modeled using iPSC-MP. However, even though results in animal models have shown improvement from previous work with isolated adult myoblasts, major challenges regarding host response have to be addressed and clinically relevant transplantation protocols are lacking. Despite these challenges we are closer than we think to bringing iPSC-MP towards clinical use for treating human muscle disease and sporting injuries.
View Full-Text
Keywords:
induced pluripotent stem cells; skeletal muscle; muscular dystrophy; myogenic progenitors; stem cell therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
MDPI and ACS Style
Roca, I.; Requena, J.; Edel, M.J.; Alvarez-Palomo, A.B. Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy. J. Clin. Med. 2015, 4, 243-259. https://doi.org/10.3390/jcm4020243
AMA Style
Roca I, Requena J, Edel MJ, Alvarez-Palomo AB. Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy. Journal of Clinical Medicine. 2015; 4(2):243-259. https://doi.org/10.3390/jcm4020243
Chicago/Turabian StyleRoca, Isart, Jordi Requena, Michael J. Edel, and Ana Belén Alvarez-Palomo. 2015. "Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy" Journal of Clinical Medicine 4, no. 2: 243-259. https://doi.org/10.3390/jcm4020243
Find Other Styles
